Adjuvant Treatment of Colon Cancer: Past, Present and Future

References

• Jemal A, Tiwari R, Murray T, et al. Cancer Statistics, 2004. Ca Cancer J Clin 2004; 54: 8–29.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13: 2936-43.
   Google Scholar
• O'Connell MJ, Maillart JA, Kahn MJ, et al Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer J Clin Oncol 1997; 15: 246-50.
   Google Scholar
• Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899–906.
   PubMed Web of Science ®Google Scholar
• Zoetmulder FAN, Taal BC, van Tinteren H, on behalf of the NACCP. Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim analysis of the Netherlands Adjuvant Colorectal Cancer Project (NACCP) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 266a (abstr).
   Google Scholar
• International Multicentre Pooled Analysis of Colorectal Cancer Trials (IMPACT). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–44.
   Google Scholar
• Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87.
   Google Scholar
• O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomised trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295–300.
   PubMed Web of Science ®Google Scholar
• Haller D, Catalano P, MacDonald J, Mayer R. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adju-vant therapy for colon cancer: Five-year final report of INT-0089 . Proc Am Soc Clin Oncol 1998; 17: 256a (abstr).
   Google Scholar
• Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucov-orin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553–9.
   PubMed Web of Science ®Google Scholar
• Quasar Collaborative Group. Comparison of fluorouracil with additional levamisole, higher dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet 2000; 355: 1588–96.
   PubMed Web of Science ®Google Scholar
• Wils J, O'Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century: European and USperspectives. Ann Oncol 2001; 12: 13–22.
   PubMed Web of Science ®Google Scholar
• Wils JA. High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? Sem Oncol 1992; 19: 2 (suppl 3), 126-30.
   Google Scholar
• Köhne C-H, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin in advanced colorectal can-cer: European Organization of Research and Treatment of Cancer Gastrointestinal Group study 40952. J Clin Oncol 2003; 21: 3721–8.
   PubMed Web of Science ®Google Scholar
• De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997; 15: 808–15.
   PubMed Web of Science ®Google Scholar
• The Meta-analysis Group in Cancer. Efficacy of intra-venous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–8.
   Google Scholar
• The Meta-analysis Group in Cancer. Toxicity of fluo-rouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537–41.
   Google Scholar
• Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 random-ized trial of fluorouracil, leucovorin and levamisole versus fluo-rouracil continuous infusion and levamisole for adjuvant treat-ment of stage III and high risk stage II colon cancer. J Clin Oncol 2005; 23: 1819-25,.
   Google Scholar
• Saini A, Norman AR, Cunningham D, et al. Twelve weeks of protracted venous infusion of fluorouracil is as effec-tive as 6 months of bolus 5FU and folinic acid as adjuvant treatment for colorectal cancer. Br J Cancer 2003;16 :1859-65.
   Google Scholar
• Andre T, Colin P, Louvet C, et al Semi-monthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomised trial J Clin Oncol 2003; 21: 2896-2903.
   Google Scholar
• Carrato A, Kohne C, Bedenne L, et al. Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treate-ment of patients with UICC stage III colon cancer: preliminary analysis of the PETACC-2 study. J Clin Oncol 2006; 24: suppl 185,161s (abstr).
   Google Scholar
• Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment in stage III colon cancer New Engl J Med 2005; 352: 2696-2704.
   Google Scholar
• Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project protocol C-06. J Clin Oncol 2006; 24 :2059-64.
   Google Scholar
• Kohne C-H, Folprecht G. On prejudice and facts and choices. Ann Oncol 2006; 17: 185–7
   PubMed Web of Science ®Google Scholar
• International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17: 1356–63.
   PubMedGoogle Scholar
• Gray RG, Barnwell J, Hills R, and et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observa-tion including 3238 colorectal cancer patients. Proc Am Soc Clin Oncol 2004; 23: 246(abstr).
   Google Scholar
• Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four national surgical adjuvant breast and bowel project adju-vant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-55.
   Google Scholar
• Harrington DP. The tea leaves of small trials. J Clin Oncol 1999; 17: 1336–8.
   PubMed Web of Science ®Google Scholar
• Buyse M, Piedbois P. Should Dukes B patients receive adjuvant therapy? A statistical perspective. Sem Oncol 2001; 28 (suppl 1):20-4.
   Google Scholar
• Salz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C 89803) Proc Am Soc Clin Oncol 2004; 23:246 (abstr).
   Google Scholar
• Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-flu-orouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC-3). J Clin Oncol 2005; 23: suppl 165,3s(abstr).
   Google Scholar
• Ychou M, Raoul J-L, Douillart J-Y, et al. A phase III randomized trial of LV5FU2 +CPT-11 vs. LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord 02/FFCD9802) J Clin Oncol 2005; 23: suppl 165,246s(abstr).
   Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–51.
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand S, Kuebler J-P, et al A phase III trial comparing FU/LV to FU/LV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J Clin Oncol 2005; 23: suppl 16S, 246s (abstr).
   Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004; 351: 337–45.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher N, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502–8.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: 2004 Safety Alerts for Drugs, Biologics, Medical Devices and Dietary Supplements. http://www.fda.gov/medwatch/SAFE-TY/2004/safety04.htm#avastin.
   Google Scholar
• Douillart J-Y, Bennouna J. Adjuvant chemotherapy for colon cancer: a confusing area. Ann Oncol 2005; 16: 1853–
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary endpoint for adju-vant colon cancer studies : individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-70.
   Google Scholar
• Chua YJ, Sargent D, Cunningham D. Definition of dis-ease-free survival : this is my truth-show me yours. Ann Oncol 2005; 16: 1719–21.
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004,22,1797-1806.
   Google Scholar